A Study to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics (PK) in Healthy Adult Participants

Exclusion Criteria

• - Participant is mentally or legally incapacitated, or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
• - Participant has any of the following contraindications for the SmartPill: A history of gastric bezoars, swallowing disorder, suspected or known strictures, fistulas or physiological/mechanical gastrointestinal (GI) obstruction, history of GI surgery within 3 months of administration, severe dysphagia to food or pills, Crohn’s disease or diverticulitis, cardiac pacemakers or other implanted electromedical devices.
• - History or presence of alcoholism or drug abuse within the past 2 years before screening
• - History of bleeding diathesis
• - History of gastric motility disorder for example delayed gastric emptying, dumping syndrome, or irritable bowel disease.
• - History of constipation within the last year before enrollment
• - Currently experiencing, or experienced within 2 weeks of enrollment, Grade 2 diarrhea
• - Women who are pregnant or breastfeeding
• - Positive urine drug or alcohol results at screening or check-in
• - Positive urine cotinine at screening.
• - Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).
• - Seated blood pressure is < 90/40 mmHg or > 140/90 mmHg at screening.
• - Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening.
• - Have been on a diet incompatible with the on study diet, in the opinion of the principal investigator (PI), within the 28 days before the first dose of study drug, and throughout the study.
• - Unable to refrain from or anticipates the use of protocol defined medications.
• - History or presence of liver disease and clostridium difficile-associated diarrhea.
• -